Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Adult Subjects With Hemophilia A and B Subjects With an Inhibitor

Trial Profile

Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Adult Subjects With Hemophilia A and B Subjects With an Inhibitor

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Marzeptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Sponsors Catalyst Biosciences
  • Most Recent Events

    • 01 Mar 2018 According to a Catalyst Biosciences media release, interim data from this trial are expected to be announced in July 2018.
    • 04 Jan 2018 According to a Catalyst Biosciences media release, interim data is expected to be announced in the first half of 2018.
    • 04 Jan 2018 Status changed from planning to recruiting, according to a Catalyst Biosciences.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top